Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 3, 2019, covering events occurring between May 24, 2019, and June 6, 2019. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in San Francisco, California. The report primarily addresses a material modification to the rights of security holders via a reverse stock split and recent regulatory disclosures.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance actions and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-70 reverse stock split of the Company's issued and outstanding Common Stock. This action was authorized by stockholders at the 2019 Annual Meeting on May 24, 2019.
- Effective Date: The Certificate of Fifth Amendment to the Certificate of Incorporation was filed on June 3, 2019, making the reverse stock split effective on June 7, 2019.
- Share Reclassification: Every 70 shares of pre-split Common Stock will be reclassified into 1 share of post-split Common Stock. No fractional shares will be issued; instead, cash payments will be made in lieu of fractional shares.
- Trading Adjustments: Trading on The NASDAQ Capital Market resumed on a reverse stock split-adjusted basis on June 7, 2019, under the new CUSIP number 47010C409.
- Debt Offering Disclosure: On June 5, 2019, the Company issued a press release regarding an offering of promissory notes to select accredited investors.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or outlook projections. Management commentary is limited to the execution of the reverse stock split and the notification of the promissory note offering. The primary risk highlighted is the dilution of share count and the administrative process for exchanging certificates, though brokerage account holders are not required to take action. The press releases referenced in Item 7.01 are furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the new CUSIP number (47010C409) for post-split trading.
- Confirm the exact effective date of the reverse stock split (June 7, 2019) for settlement purposes.
- Review the terms of the promissory note offering referenced in the June 5, 2019 press release (Exhibit 99.1).
- Check for cash-in-lieu-of-fractional-share payments if holding a number of shares not divisible by 70.
- Confirm that the Company remains listed on The NASDAQ Capital Market following the split.